Anti-transferrin receptor antibodies with tailored affinity

Patent metadata

Field	Value
Publication number	US-12252533-B2
Application number	US-202218069838-A
Country	US
Kind code	B2
Filing date	Dec 21, 2022
Priority date	Jun 24, 2015
Publication date	Mar 18, 2025
Grant date	Mar 18, 2025

Abstract

Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.

First claim

The invention claimed is:

1. A humanized antibody that specifically binds to human transferrin receptor (TfR), wherein the antibody comprises
in the heavy chain variable domain the hypervariable regions (HVRs) of SEQ ID NOs: 66, 68 and 71, and
in the light chain variable domain the HVRs of SEQ ID NOs: 75, 76 and 78.

2. The humanized antibody according to claim 1 , comprising a heavy chain variable domain of SEQ ID NO: 23 and a light chain variable domain of SEQ ID NO: 37.

3. The humanized antibody according to claim 1 , wherein the humanized antibody specifically binds to human transferrin receptor and to cynomolgus transferrin receptor.

4. The humanized antibody according to claim 1 , wherein the humanized antibody is a multispecific antibody having at least one binding specificity for the human transferrin receptor and at least one binding specificity for a therapeutic target.

5. The humanized antibody according to claim 4 , wherein the humanized antibody comprises a first antigen binding site which binds the human transferrin receptor and a second antigen binding site which binds a brain antigen.

6. The humanized antibody according to claim 5 , wherein the humanized antibody is a bispecific antibody comprising
i) a first binding site binding to human transferrin receptor and comprising a heavy chain variable domain of SEQ ID NO: 23 and a light chain variable domain of SEQ ID NO: 37,
and
ii) a second binding site
a) binding to Abeta and comprising a heavy chain variable domain of SEQ ID NO: 81 and a light chain variable domain of SEQ ID NO: 82, or
b) binding to alpha-synuclein and comprising a heavy chain variable domain of SEQ ID NO: 83 and a light chain variable domain of SEQ ID NO: 84, or
c) binding to alpha-synuclein and comprising a heavy chain variable domain of SEQ ID NO: 85 and a light chain variable domain of SEQ ID NO: 86, or
d) binding to alpha-synuclein and comprising a heavy chain variable domain of SEQ ID NO: 87 and a light chain variable domain of SEQ ID NO: 88, or
e) binding to alpha-synuclein and comprising a heavy chain variable domain of SEQ ID NO: 91 and a light chain variable domain of SEQ ID NO: 92, or
f) binding to alpha-synuclein and comprising a heavy chain variable domain of SEQ ID NO: 89 and a light chain variable domain of SEQ ID NO: 90, or
g) binding to alpha-synuclein and comprising a heavy chain variable domain of SEQ ID NO: 93 and a light chain variable domain of SEQ ID NO: 94, or
h) binding to CD20 and comprising a heavy chain variable domain of SEQ ID NO: 79 and a light chain variable domain of SEQ ID NO: 80.

7. The humanized antibody according to claim 1 , wherein the humanized antibody is
a) a full length antibody of the human subclass IgG1, or
b) a full length antibody of the human subclass IgG4, or
c) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G,
d) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and optionally P329G,
e) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain, or
f) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and optionally P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain.

8. The humanized antibody according to claim 1 , wherein the humanized antibody comprises
i) a homodimeric Fc-region of the human IgG1 subclass optionally with the mutations P329G, L234A and L235A, or
ii) a homodimeric Fc-region of the human IgG4 subclass optionally with the mutations P329G, S228P and L235E, or
iii) a heterodimeric Fc-region whereof
a) one Fc-region polypeptide comprises the mutation T366W, and the other Fc-region polypeptide comprises the mutations T366S, L368A and Y407V, or
b) one Fc-region polypeptide comprises the mutations T366W and Y349C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or
c) one Fc-region polypeptide comprises the mutations T366W and S354C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V and Y349C,
or
iv) a heterodimeric Fc-region of the human IgG4 subclass whereof both Fc-region polypeptides comprise the mutations P329G, L234A and L235A and
a) one Fc-region polypeptide comprises the mutation T366W, and the other Fc-region polypeptide comprises the mutations T366S, L368A and Y407V, or
b) one Fc-region polypeptide comprises the mutations T366W and Y349C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or
c) one Fc-region polypeptide comprises the mutations T366W and S354C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V and Y349C,
or
v) a heterodimeric Fc-region of the human IgG4 subclass whereof both Fc-region polypeptides comprise the mutations P329G, S228P and L235E and
a) one Fc-region polypeptide comprises the mutation T366W, and the other Fc-region polypeptide comprises the mutations T366S, L368A and Y407V, or
b) one Fc-region polypeptide comprises the mutations T366W and Y349C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V, and S354C, or
c) one Fc-region polypeptide comprises the mutations T366W and S354C, and the other Fc-region polypeptide comprises the mutations T366S, L368A, Y407V and Y349C.

9. A pharmaceutical formulation comprising the humanized antibody according to claim 1 and a pharmaceutically acceptable carrier.

10. A pharmaceutical formulation comprising the humanized antibody according to claim 2 and a pharmaceutically acceptable carrier.

11. A pharmaceutical formulation comprising the humanized antibody according to claim 6 and a pharmaceutically acceptable carrier.

Assignees

• Hoffmann La Roche

Inventors

• Dengl Stefan
• Georges Guy
• Goepfert Ulrich
• Niewoehner Jens
• Schlothauer Tilman

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/2881 Primary

  against CD71 · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title